Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Talecris Immunoglobulin Therapy Gains Priority Review For CIDP

This article was originally published in The Pink Sheet Daily

Executive Summary

Supplemental BLA for chronic inflammatory demyelinating polyneuropathy has Sept. 13 user fee date.

You may also be interested in...



Talecris’ Gamunex Gets Leg Up In CIDP

Immune globulin’s broader label sure to please merger-bound CSL.

Talecris’ Gamunex Gets Leg Up In CIDP

Immune globulin’s broader label sure to please merger-bound CSL.

Bayer To Retain Kogenate Line Following Plasma Unit Spin-Off

Company divests plasma products business to NPS BioTherapeutics under a $590 mil. agreement. Bayer will receive 10% equity in NPS, a new corporation formed by Cerebus Capital Management and Ampersand Ventures.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel